Untitled record
Abstract
This record has no abstract on file.
Term
Term ended
Expired 21 April 1987, 39.4 years ago.
- Priority and filed
- Granted
- Expired
- Today
2 claims: 2 independent, 0 dependent
- 1ABSTRACT RÉSUMÉ 1. Medicinal product which can be used in particular for the treatment of asthenia and liver failure, this medicinal product comprising, as active ingredient, the addition salt of Z-citrulline with malic acid in the molecular proportion 1:1. 1° Médicament utilisable notamment pour le traitement des asténies et des insuffisances hépatiques, ce médicament comprenant, en tant que principe actif, le sel d’addition de Z-citrulline à l’acide malique dans la proportion moléculaire 1 :1.
- 22 ° Parmaceutical forms of medicament specified under 1 °, in which the active principle is combined with a solid or liquid excipient for oral administration (in particular tablets and oral solutions) or with a liquid for parenteral administration or with an excipient for endorectal administration . 2° Formes parmaceutiques de médicament spécifié sous 1°, dans lesquelles le principe actif est associé à un excipient solide ou liquide pour l’administration orale (notamment comprimés et solutions buvables) ou à un liquide pour administration parentérale ou à un excipient pour administration endorectale. Said company:HUBLOT ET VALLET, Société dite : HUBLOT ET VALLET, SOCIETE EN NOM COLLECTIF (known under the trade name "DIMAPHAR") By proxy: SOCIÉTÉ EN NOM COLLECTIF (connue sous la dénomination commerciale «DIMAPHAR») Par procuration : J. Casanova (Armengaud Young Cabinet) J. Casanova (Cabinet Armengaud jeune)
Independent claims2
24 paragraphs in 4 sections, as filed
FRENCH REPUBLIC
MINISTRY OF INDUSTRY
INDUSTRIAL PROPERTY SERVICE
SPECIAL MEDICINAL PATENT
PV n ° 103.677 N ° 6.443 M
International classification: A 61 k // C 07 c
Medication based on malic acid and eitrulline derivative.
So-called company: HUBLOT ET VALLET, Société en Nom Collectif (known under the trade name "DIMAPHAR") residing in France (Yvelines).
Requested on April 21, 1967, at 2 p.m.<sup>h</sup> 33<sup>m</sup>, in Paris.
Issued by decree of November 12, 1968.
(Official Bulletin of Industrial Property [BSM], No. 51 of December 16, 1968.)
The special feature of this medicine is malic acid in the molecular ratio 1: 1. contain, as active ingredient, a new compound. This salt can be represented by the following formula: calf which is the addition salt of Z-citrulline to / NH<sub>2</sub>
HOO-CHOH-CH<sub>2</sub>-COOH, H<sub>2</sub>N-CO-NH- (CH<sub>2</sub>) 3-CHf 'COOH
It can be prepared by reaction of Z-malic acid and Z-citrulline in equimolar proportion, in particular as described in the following example, which is not limiting.
Example. - Dissolve in water at 50 °, on the one hand, 8.7 g of Z-citrulline, on the other hand, 6.2 g of Z-malic acid. The two solutions are mixed; the reaction takes place quickly. The water is evaporated by lyophilization and 15 g of Z-citrulline malate are obtained.
The melting point of this compound is 100 ° (pasty fusion). It is soluble in water.
The toxicity of Z-citrulline malate is low, the LD 50 in mice (intraperitoneal route) being greater than 2000 mg / kg.
The 220 mg / kg intraperitoneal injection results in 85% protection from seizures and death in rats with ammonium chloride-induced experimental hyperammonemia.
The subcutaneous injection of 450 mg / kg of Z-citrulline malate significantly improves the endurance of the swimming test rat.
Z-citrulline Z-malate may be used, inter alia, for the purpose of causing increased elimination of toxic ammonium ions in states of fatigue or hyperammonemia.
It can be used, more particularly and without these examples being limiting in the following cases:
Hepatic insufficiency ;
Hyperammonemic states;
Asthenia and physical fatigue;
210287 7 ♦
Asthenia and fatigue due to protein anaholicism disorder.
The new compound can be presented in the form of a 10 to 20% aqueous solution for injection (its pH is 6.4), in the form of a 10% oral solution, in the form of dragees or capsules containing from 0.30 to 1 g of active substance or in the form of suppositories to 1 g of active substance.
The average daily doses are 0.50 to 3 g of active substance.
Contents4
Every citation, both ways
| Document | Relation | Office | Cited during |
|---|---|---|---|
| EP1270003A1 | Cited by | European Patent Office (EPO) | Search report |
| WO2007027213A1 | Cited by | World Intellectual Property Organization (WIPO) | International search |
| US7794770B2 | Cited by | United States of America | Applicant |
| US7799363B2 | Cited by | United States of America | Applicant |
| US7842326B2 | Cited by | United States of America | Applicant |
| WO2007027213A1 | Cited by | World Intellectual Property Organization (WIPO) | Search report |
| US7897192B2 | Cited by | United States of America | Applicant |
| FR2691359A1 | Cited by | France | Search report |
| US7906160B2 | Cited by | United States of America | Applicant |
| EP1270003A1 | Cited by | European Patent Office (EPO) | Search report |
1 legal event, as the office reported them to INPADOC
Events
| Event | Code | |
|---|---|---|
| Concession to grant licencesCL | CL |
Numbers
- Application
- 103677
Classification
- CPC, 1
- C07C59/245
- IPC, 1
- C07C59 245